작성일 : 14-09-21 14:44
| 연구단계 | 1단계 :1년차 | ||
| 논문제목(영문) | Cilostazol protects vessels against hyperglycemic injury and accelerates healing after implantation of drug-eluting stent in a type 1 diabetes mellitus rat aorta stent model. | ||
| 국내외구분 | 국외 | SCI여부 | SCI |
| 연구책임자역활 | 교신저자 | 논문기여율 | 30% |
| 주저자명 | Kwon JS | ||
| 교신저자명 | Ahn Y | ||
| 공동저자명 | Kim YS, Cho HH, Kee HJ, Hong MH, Kang WS, Jeong HY, Jeong MH | ||
| 게제년월일 | 2013-06-01 | ||
| ISSN | 0021-9150 | ||
| Impact Factor | 3.971 | ||
| 학술지명 | Atherosclerosis | ||
| 서지사항 | 0집 / 228권 / 2호, 페이지(332 - 338) | ||
| 병기표기 | 단독 | ||
| Acknowledgement 기재여부 |
예
※ Acknowledgement가 기재된 논문만 연구과제의 성과로 인정. - 국문 표기 : "본 연구는 보건복지부 보건의료연구개발사업의 지원에 의하여 이루어진 것임. (HI13C1527)" - 영문 표기 : "This study was supported by a grant of the Korean Health Technology R&D Project, (HI13C1527) Ministry of Health & Welfare, Republic of Korea. " |
||
| 요약초록문 (Abstract) 입력 |
(Abstract) 입력 OBJECTIVE: Cilostazol, a selective phosphodiesterase-3 (PDE-3) inhibitor, can effectively suppress platelet activation and attenuate the increase in carotid intima-media thickness in diabetes mellitus (DM) patients. Therefore, we investigated whether cilostazol had effects on the healing process after implantation of a drug-eluting stent (DES) in a rat model of type 1 DM. METHODS AND RESULTS: Streptozotocin-induced DM rats were divided into 2 groups in which cilostazol (30 mg/kg/day; DM-Cilostazol) or vehicle (DM-Vehicle) was orally administered. Age-matched rats treated with the vehicle were used as a control group (NDM-Vehicle). After 4 weeks, cilostazol changed the expression of vascular cell adhesion molecule and intercellular adhesion molecule and the apoptotic cell ratio of the media (DM-Vehicle: 53.5 ± 9.8%, DM-Cilostazol: 26.4 ± 8.3%, p < 0.05) in the aortic wall. Also, in a modified aortic ring test, cilostazol preserved the angiogenic potential of the aorta ([height of the sprouting tubes] DM-Vehicle: 0 ± 0 μm, DM-Cilostazol: 344.6 ± 236.8 μm, p < 0.05). After implantation of paclitaxel-eluting stents (PES) in rats treated with cilostazol or vehicle, thrombus formation, deposition of fibrin, and infiltration of inflammatory cells were attenuated by cilostazol. In particular, the re-endothelialization by von Willebrand factor expression in the DM-PES-Cilostazol group was enhanced compared with that in the DM-PES-Vehicle group. CONCLUSION: Cilostazol has potential for protecting vessels against hyperglycemic injury and for accelerating the healing process after implantation of DES. |
||
